利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

20 条记录 (耗时 0.017 秒)

    Docetaxel formulations with lipoic acid
    1.
    发明授权
    Docetaxel formulations with lipoic acid 有权
    多西他赛制剂与硫辛酸

    公开(公告)号：US08476310B2

    公开(公告)日：2013-07-02

    申请号：US12721564

    申请日：2010-03-11

    申请人： Nagesh Palepu

    发明人： Nagesh Palepu

    IPC分类号： A61K31/337

    CPC分类号： A61K31/337 ,  A61K9/0019 ,  A61K9/08 ,  A61K47/10 ,  A61K47/12 ,  A61K47/44

    摘要： Pharmaceutical formulations comprising docetaxel, solubilizer, and α-lipoic acid, wherein the formulation is substantially free of polysorbates and polyethoxylated castor oil. The solubilizer may comprise glycofurol, acetic acid, benzyl alcohol, or ethanol. The α-lipoic acid, at certain concentrations, may impart stability and prevent degradation of docetaxel while the formulations are in storage. The formulations may be combined with a diluent, which comprises one or more hydrotropes such as tocopherol polyethylene glycol succinate and polyethylene glycol. The formulations combined with the diluent also exhibit stability after storage. Methods of administering docetaxel comprise preparing the formulation comprising docetaxel, solubilizer, and α-lipoic acid; mixing the formulation with a diluent; diluting the resulting formulation in saline, water for injection, or the like; and then injecting the formulations into patients in need thereof.

    摘要翻译： 包含多西紫杉醇，增溶剂和α-硫辛酸的药物制剂，其中所述制剂基本上不含聚山梨醇酯和聚乙氧基化蓖麻油。 增溶剂可以包含糖福，乙酸，苄醇或乙醇。 某些浓度的α-硫辛酸可以赋予稳定性并且在制剂储存时防止多西紫杉醇的降解。 制剂可与稀释剂组合，稀释剂包含一种或多种水溶助长剂如生育酚聚乙二醇琥珀酸酯和聚乙二醇。 与稀释剂组合的制剂在储存后也表现出稳定性。 给予多西紫杉醇的方法包括制备包含多西他赛，增溶剂和α-硫辛酸的制剂; 将制剂与稀释剂混合; 将所得制剂稀释在盐水，注射用水等中; 然后将制剂注射到有需要的患者体内。

    READY-TO-USE BIVALIRUDIN COMPOSITIONS
    2.
    发明申请
    READY-TO-USE BIVALIRUDIN COMPOSITIONS 审中-公开
    准备使用双维生素组合物

    公开(公告)号：US20110046063A1

    公开(公告)日：2011-02-24

    申请号：US12856088

    申请日：2010-08-13

    申请人： Nagesh PALEPU ,  Rajeshwar MOTHERAM ,  Praful SHAH ,  Gopal KRISHNA

    发明人： Nagesh PALEPU ,  Rajeshwar MOTHERAM ,  Praful SHAH ,  Gopal KRISHNA

    IPC分类号： A61K38/10 ,  A61P9/00

    CPC分类号： A61K38/58

    摘要： Ready-to-use bivalirudin compositions, methods of using the ready-to-use bivalirudin compositions, and methods of preparing the ready-to-use bivalirudin compositions. The ready-to-use bivalirudin compositions comprise bivalirudin and one or more stabilizing agents. The one or more stabilizing agents may be buffering agents having a pKa of about 2.5 to about 6.5, pH-adjusting agents, polymers, preservatives, antioxidants, sugars or polyols, or a combination thereof. The ready-to-use bivalirudin compositions may also comprise [9-10]-cycloimido bivalirudin, [11-12]-cycloimido bivalirudin, or a combination thereof. The method of using the ready-to-use bivalirudin compositions comprises administering the ready-to-use compositions to a patient in need thereof. Further, the method of preparing the ready-to-use bivalirudin compositions comprises mixing bivalirudin with one or more stabilizing agents.

    摘要翻译： 即用比伐卢定组合物，使用即用比伐卢定组合物的方法，以及制备即用型比伐卢定组合物的方法。 即用型比伐卢列组合物包含比伐卢定和一种或多种稳定剂。 一种或多种稳定剂可以是pKa为约2.5至约6.5的缓冲剂，pH调节剂，聚合物，防腐剂，抗氧化剂，糖或多元醇或其组合。 即用型比伐卢定组合物还可以包含[9-10] - 环亚氨基比伐卢定，[11-12] - 环亚氨基比伐卢定或其组合。 使用即用比伐卢定组合物的方法包括将即用组合物给予有需要的组合物。 此外，制备即用型比伐卢定组合物的方法包括将比伐卢定与一种或多种稳定剂混合。

    Docetaxel formulations with lipoic acid
    3.
    发明授权
    Docetaxel formulations with lipoic acid 有权
    多西他赛制剂与硫辛酸

    公开(公告)号：US07772274B1

    公开(公告)日：2010-08-10

    申请号：US12721563

    申请日：2010-03-11

    申请人： Nagesh Palepu

    发明人： Nagesh Palepu

    IPC分类号： A61K31/337

    CPC分类号： A61K31/337 ,  A61K9/0019 ,  A61K47/10 ,  A61K47/12

    摘要： Pharmaceutical formulations comprising docetaxel, solubilizer, and α-lipoic acid, wherein the formulation is substantially free of polysorbates and polyethoxylated castor oil. The solubilizer may comprise glycofurol, acetic acid, benzyl alcohol, or ethanol. The α-lipoic acid, at certain concentrations, may impart stability and prevent degradation of docetaxel while the formulations are in storage. The formulations may be combined with a diluent, which comprises one or more hydrotropes such as tocopherol polyethylene glycol succinate and polyethylene glycol. The formulations combined with the diluent also exhibit stability after storage. Methods of administering docetaxel comprise preparing the formulation comprising docetaxel, solubilizer, and α-lipoic acid; mixing the formulation with a diluent; diluting the resulting formulation in saline, water for injection, or the like; and then injecting the formulations into patients in need thereof.

    摘要翻译： 包含多西紫杉醇，增溶剂和α-硫辛酸的药物制剂，其中制剂基本上不含聚山梨醇酯和聚乙氧基化蓖麻油。 增溶剂可以包含糖福，乙酸，苄醇或乙醇。 某些浓度的α-硫辛酸可以在制剂储存时赋予稳定性并防止多西紫杉醇的降解。 制剂可与稀释剂组合，稀释剂包含一种或多种水溶助长剂如生育酚聚乙二醇琥珀酸酯和聚乙二醇。 与稀释剂组合的制剂在储存后也表现出稳定性。 给予多西紫杉醇的方法包括制备包含多西紫杉醇，增溶剂和α-硫辛酸的制剂; 将制剂与稀释剂混合; 将所得制剂稀释在盐水，注射用水等中; 然后将制剂注射到有需要的患者体内。

    STABLE PHARMACEUTICAL COMPOSITIONS, PROCESSES FOR MAKING THE SAME AND METHODS OF THEIR USE
    4.
    发明申请
    STABLE PHARMACEUTICAL COMPOSITIONS, PROCESSES FOR MAKING THE SAME AND METHODS OF THEIR USE 失效
    稳定的药物组合物，制备它们的方法及其使用方法

    公开(公告)号：US20070190085A1

    公开(公告)日：2007-08-16

    申请号：US11743262

    申请日：2007-05-02

    申请人： Nagesh PALEPU

    发明人： Nagesh PALEPU

    IPC分类号： A61K31/34 ,  A61K9/00

    CPC分类号： A61K9/0095 ,  A61K9/08 ,  A61K31/34 ,  A61K47/36 ,  A61K47/38

    摘要： The present invention is generally related to alcohol free, liquid ranitidine formulations for oral administration. In particular, the present invention is related to stable, syrup formulations having ranitidine as an active ingredient for oral administration, processes for making the same, and methods of their use. The ranitidine of the present invention is stable in non-polar media or media having a relatively low polarity such that the dielectric constant is less than about 60, and is achieved by using certain saccharides, certain relatively high molecular weight starches, and/or certain celluloses instead of alcohol.

    摘要翻译： 本发明通常涉及无酒精的用于口服给药的液体雷尼替丁制剂。 特别地，本发明涉及具有雷尼替丁作为口服给药的活性成分的稳定的糖浆制剂，其制备方法及其使用方法。 本发明的雷尼替丁在具有相对低极性的非极性介质或介质中是稳定的，使得介电常数小于约60，并且通过使用某些糖，某些相对高分子量的淀粉和/或某些 纤维素代替酒精。

    Docetaxel Formulations with Lipoic Acid
    7.
    发明申请
    Docetaxel Formulations with Lipoic Acid 有权
    多西他赛制剂与硫辛酸

    公开(公告)号：US20110092581A1

    公开(公告)日：2011-04-21

    申请号：US12721564

    申请日：2010-03-11

    申请人： Nagesh Palepu

    发明人： Nagesh Palepu

    IPC分类号： A61K31/337 ,  A61P35/00

    CPC分类号： A61K31/337 ,  A61K9/0019 ,  A61K9/08 ,  A61K47/10 ,  A61K47/12 ,  A61K47/44

    摘要： Pharmaceutical formulations comprising docetaxel, solubilizer, and α-lipoic acid, wherein the formulation is substantially free of polysorbates and polyethoxylated castor oil. The solubilizer may comprise glycofurol, acetic acid, benzyl alcohol, or ethanol. The α-lipoic acid, at certain concentrations, may impart stability and prevent degradation of docetaxel while the formulations are in storage. The formulations may be combined with a diluent, which comprises one or more hydrotropes such as tocopherol polyethylene glycol succinate and polyethylene glycol. The formulations combined with the diluent also exhibit stability after storage. Methods of administering docetaxel comprise preparing the formulation comprising docetaxel, solubilizer, and α-lipoic acid; mixing the formulation with a diluent; diluting the resulting formulation in saline, water for injection, or the like; and then injecting the formulations into patients in need thereof.

    摘要翻译： 包含多西紫杉醇，增溶剂和α-硫辛酸的药物制剂，其中制剂基本上不含聚山梨醇酯和聚乙氧基化蓖麻油。 增溶剂可以包含糖福，乙酸，苄醇或乙醇。 某些浓度的α-硫辛酸可以在制剂储存时赋予稳定性并防止多西紫杉醇的降解。 制剂可与稀释剂组合，稀释剂包含一种或多种水溶助长剂如生育酚聚乙二醇琥珀酸酯和聚乙二醇。 与稀释剂组合的制剂在储存后也表现出稳定性。 给予多西紫杉醇的方法包括制备包含多西紫杉醇，增溶剂和α-硫辛酸的制剂; 将制剂与稀释剂混合; 将所得制剂稀释在盐水，注射用水等中; 然后将制剂注射到有需要的患者体内。

    Parathyroid hormone analogues and methods of use
    8.
    发明申请
    Parathyroid hormone analogues and methods of use 审中-公开
    甲状旁腺激素类似物和使用方法

    公开(公告)号：US20090042774A1

    公开(公告)日：2009-02-12

    申请号：US11799816

    申请日：2007-05-02

    申请人： Paul Morley ,  Martin Stogniew ,  Brian MacDonald ,  Gene Scott Merutka ,  Nagesh Palepu

    发明人： Paul Morley ,  Martin Stogniew ,  Brian MacDonald ,  Gene Scott Merutka ,  Nagesh Palepu

    IPC分类号： A61K38/29 ,  A61P19/00

    CPC分类号： A61K38/29

    摘要： The present invention is directed to novel methods of treating a subject with a bone deficit disorder. The methods generally include administering to a subject in need thereof a pharmaceutically acceptable formulation comprising a parathyroid hormone (PTH) peptide analogue in a daily dose sufficient to result in an effective pharmacokinetic profile and maintained adenylate cyclase activity, while simultaneously reducing undesirable side effects.

    摘要翻译： 本发明涉及用骨缺损障碍治疗受试者的新方法。 所述方法通常包括向有需要的受试者施用包含甲状旁腺激素（PTH）肽类似物的药学上可接受的制剂，其日剂量足以导致有效的药代动力学特征并维持腺苷酸环化酶活性，同时减少不期望的副作用。